Skip To Main Content
F. Barlesi on Muck Rack

F. Barlesi

As seen in: Color Research & Application, Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with F.

Contact F., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Targeting KRAS in non-small cell lung cancer: recent progress and new approaches

|
By M. Reck, D.P. Carbone, F. Barlesi, M. Garassino
| annalsofoncology.org
Highlights • Better understanding of RAS signaling has led to development of promising directly blocking compounds in KRAS mutant tumors • New drug candidates take advantage of the increased knowledge of KRAS mutation complex and relevant protein structures • Increasing evidence continues to demonstrate the genomic heterogeneity in KRAS-mutated NSCLC • Current efforts include understanding and overcoming resistance after treatment with KRASG12C inhibitors Abstract Rat sarcoma (RAS) is the...
Open in Who Shared Issue with article?

Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service

|
By L. Greillier, F. Barlesi, H. Capelle, C. Tummino, M. Gouitaa, J. Birnbaum, N. Ausias, M. Montana
| Color Research & Application Verified
What is known and objective With the increasing use of cancer chemotherapy agents, hypersensitivity reactions are commonly encountered. The allergic clinical symptoms are variable and unpredictable. The aim of this study was to identify the characteristics of hypersensitivity reactions and to assess the value of skin tests for platinum salts and pemetrexed in the treatment of patients with non-small cell lung cancers or malignant pleural mesothelioma.
Open in Who Shared Issue with article?

438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

|
By K. T. Park, F. Barlesi, Aix Marseille, F. Ciardiello
| Annals of Oncology Verified
Background: Atezolizumab (atezo) inhibits the binding of PD-L1 to its receptors PD-1 and B7.1, thereby restoring tumor-specific T-cell immunity, while leaving the PD-L2/PD-1 interaction intact. Atezo demonstrated survival benefit vs docetaxel (doc) in the Ph2 trial POPLAR. Here we present the primary analysis from the Ph3 OAK study evaluating atezo vs doc in previously treated NSCLC.
Open in Who Shared Issue with article?
See all 15 articles